ASTRAZEN — Astrazeneca Pharma India Income Statement
0.000.00%
Last trade - 00:00
- IN₹129.74bn
- IN₹124.46bn
- IN₹10.03bn
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,283 | 8,318 | 8,136 | 8,056 | 10,030 |
Cost of Revenue | |||||
Gross Profit | 4,504 | 4,897 | 4,757 | 4,400 | 5,722 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6,717 | 7,293 | 6,977 | 7,362 | 8,943 |
Operating Profit | 566 | 1,026 | 1,159 | 694 | 1,086 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 727 | 1,140 | 1,271 | 830 | 1,341 |
Provision for Income Taxes | |||||
Net Income After Taxes | 545 | 722 | 933 | 616 | 993 |
Net Income Before Extraordinary Items | |||||
Net Income | 545 | 722 | 933 | 616 | 993 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 545 | 722 | 933 | 616 | 993 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 21.8 | 28.8 | 36.7 | 23.8 | 50.9 |
Dividends per Share |